QUVIVIQ is a global product, delivering restorative nights and revitalized days to thousands of patients living with insomnia. Each market where QUVIVIQ is available presents its own opportunities and challenges. We must break down the barriers to prescription wherever we find them, to unlock the value of QUVIVIQ for patients, healthcare providers, and the company. Furthermore, our teams must proactively profile the safety and efficacy of daridorexant in specific patient populations, giving physicians all the information they need to make their prescribing decisions.
QUVIVIQ
Unlocking the value of QUVIVIQ
“Commercial efforts with QUVIVIQ, Europe’s first and only dual orexin receptor antagonist, are beginning to translate into promising success.”
— Benjamin Limal, President of EUCAN region
Partners
Nurturing strong alliances
Partner-led Portfolio
“Over the last few years, we have engaged in several important strategic partnerships. We often retain a vested interest in the success of our partnered products, which means that our alliances are of increasing importance to the company.”
— André C. Muller, CEO
Idorsia engages in strong strategic partnerships, tapping into external resources to realize our objective of changing the treatment paradigm in underserved disorders. Whether such alliances are designed to support new discoveries, develop our compounds, or commercialize our products, we aim to be proactive and contribute to their success wherever possible. As the inventors of the assets – with expert knowledge of the wealth of data created and the evidence of efficacy and safety – we have a unique perspective to share when analyzing, interpreting, and describing the science and benefits. We will engage with and support our partners so as to maximize the value of our innovation.
Pipeline
Leveraging our innovative pipeline
Assets in Idorsia’s innovative portfolio show great potential in a broad range of indications that significantly impact sizeable patient populations. To limit Idorsia’s financial commitment, we will seek partners to generate clinical evidence from the large studies required. To attract potential partners, the R&D team will generate preclinical and clinical proof-of-concept data enabling others to recognize the value of our innovation.
“We have an exciting and very unique early-stage clinical pipeline of potential transformative therapies that have come from our drug discovery group. Funding permitting, we intend to develop these to the next inflection point before finding a partner, unless a partner were to express interest already today.”
— Alberto Gimona, Executive Vice President, Head of Global Clinical Development
Idorsia-led Portfolio
Drug discovery
Targeting our drug discovery
Drug discovery is the DNA of Idorsia. Creating sustainable value as a pharmaceutical company is dependent on fueling the pipeline with innovative drugs. Powered by a specialized drug discovery engine, we focus on small-molecule therapies designed to redefine the way diseases are treated. Our leading experts have the skills to transform innovative ideas into life-changing solutions. We take discoveries from initial hits to optimized drugs with proven efficacy in disease models. We will invest in the company’s future through targeted drug discovery and clinical development up to proof of concept and – when feasible and appropriate – even
further.
“We have put our portfolio through a rigorous prioritization and limited our activities in R&D in order to make our money last. Each portfolio compound has been assessed – in the context of the competitive landscape – for the feasibility of Idorsia being able to develop alone or how we can generate preclinical and clinical proof-of-concept data enabling others
to recognize the value of the asset.”
to recognize the value of the asset.”
— Martine Clozel, CSO
Finance
Making the money last
We will exercise financial discipline, spending within our means, and thus paving the way to sustainable profitability and significant value creation. Operating expenses will be managed by adjusting the company’s activities sufficiently to ensure that the funding will sustain Idorsia as we move towards profitability.
“We have come through difficult times, and our goal remains that of becoming financially sustainable, and our current forecasts have us reaching commercial profitability with QUVIVIQ in 2026, and overall profitability in 2027.”
— Arno Groenewoud, Executive Vice President, Chief Financial Officer
Financial information
Read our latest financial reports and updates on how we will achieve sustainable profitability.
Our Innovation
Innovating from the lab bench all the way through to the patient’s bedside. Learn more about how we innovate, our portfolio and our target diseases.
Latest news
Our innovation is the basis for our long-term sustainability. Read the latest news from across our portfolio.
More joy –
The spark of passion
We want our employees to feel proud of their work, and of the company they work for. We provide a supportive and stimulating environment for high-performing teams, recognizing and rewarding their contributions.
“Achieving our strategic priorities is dependent on a company-wide effort, so we must attract, retain, and develop a talented and engaged workforce. ”
— André C. Muller, CEO
